Kura Oncology Reports Second Quarter 2017 Financial Results And Provides Update On Tipifarnib Phase II Study

Published: Aug 08, 2017

LA JOLLA, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported second quarter 2017 financial results and provided a corporate update. In the company’s ongoing Phase 2 trial of tipifarnib in patients with HRAS mutant squamous cell carcinomas of the head and neck (SCCHN), partial responses have been observed in three of five evaluable patients and two of the responses have demonstrated durability beyond one year.

Back to news